Skip to main content
Figure 1 | Alzheimer's Research & Therapy

Figure 1

From: Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Figure 1

Responder analyses for the individual assessment scales. (A) Compared with the 9.5 mg/24 h patch, the 13.3 mg/24 h patch was associated with a significantly higher proportion of patients with ≥4 point improvement on the ADAS-cog at both weeks 24 and 48. *P <0.05, 13.3 mg/24 h versus 9.5 mg/24 h patch. (B) Compared with the 9.5 mg/24 h patch, the 13.3 mg/24 h patch was associated with a significantly higher proportion of patients who showed no decline on the ADCS-IADL at Week 24. *P <0.05, 13.3 mg/24 h versus 9.5 mg/24 h patch. ADAS-cog, Alzheimer’s Disease Assessment Scale–cognitive subscale; ADCS-IADL, Instrumental domain of the Alzheimer’s Disease Cooperation Study–Activities of Daily Living scale.

Back to article page